|
|
 |
ETHYLCELLULOSES Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
RELISTOR Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
ROZLYTREK Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
EDETATE CALCIUM DISODIUM Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
RHOPRESSA Drug Profile, 2024 |
$399.00 |
|
$399.00 |
|
|